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of patients are prone to follow dietary advice from a variety of sources, including the lay press, there
is intriguingly little scientific evidence for such an incitement. This may result in physicians being
insufficiently informed about various aspects of nutrition, precluding adequate guidance of their patients
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and several micronutrients, which may even be more pronounced in patients with active disease and
those following a restrictive diet. This review aims to summarize the latest data from clinical and
epidemiological studies investigating diet and its effect on the course of the disease and to outline the
most important nutrient deficiencies in IBD patients. Key Messages: A western diet with an imbalance
between omega-6 (n-6)/omega-3 (n-3) polyunsaturated fatty acids (PUFAs), in favor of n-6 PUFAs, may
increase the risk of IBD, whereas a diet high in fruits and vegetables may decrease the risk of IBD. Many
approaches to influence the course of IBD with dietary intervention exist. However, to induce or maintain
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we can apply it in daily practice. Patients with IBD, even in remission, have to be screened regularly for
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Abstract
Background: Westernization, above all associated changes 
in diet, has been postulated to be one of the most important 
factors contributing to the increasing incidence in inflamma-
tory bowel disease (IBD), consisting mainly of Crohn’s dis-
ease and ulcerative colitis. Summary: Diet represents a cru-
cially important and intuitively relevant topic for IBD pa-
tients. Although a substantial number of patients are prone 
to follow dietary advice from a variety of sources, including 
the lay press, there is intriguingly little scientific evidence for 
such an incitement. This may result in physicians being insuf-
ficiently informed about various aspects of nutrition, pre-
cluding adequate guidance of their patients with IBD. Impor-
tantly, IBD patients are at risk to develop deficiencies in iron, 
vitamin B12, folic acid, and several micronutrients, which 
may even be more pronounced in patients with active dis-
ease and those following a restrictive diet. This review aims 
to summarize the latest data from clinical and epidemiolog-
ical studies investigating diet and its effect on the course of 
the disease and to outline the most important nutrient defi-
ciencies in IBD patients. Key Messages: A western diet with 
an imbalance between omega-6 (n-6)/omega-3 (n-3) poly-
unsaturated fatty acids (PUFAs), in favor of n-6 PUFAs, may 
increase the risk of IBD, whereas a diet high in fruits and veg-
etables may decrease the risk of IBD. Many approaches to 
influence the course of IBD with dietary intervention exist. 
However, to induce or maintain remission in IBD with a 
change of diet is still in its infancy, and more dietary research 
is needed before we can apply it in daily practice. Patients 
with IBD, even in remission, have to be screened regularly for 
malnutrition. © 2020 S. Karger AG, Basel
Introduction
The change of environmental factors, particularly the 
westernized lifestyle, combined with an alteration in diet, 
improved hygiene, vaccinations, increasing use of antibi-
otics [1], urbanization, and better access to medical supply 
as increased use of oral contraceptives [2–4], is thought to 
be one of the main drivers for the rising prevalence of in-
flammatory bowel disease (IBD) in westernized countries 
[5–9]. The highest impact of these factors to the develop-
ment of IBD is probably exerted by the shift to a western 
diet characterized by high amounts of protein and (un-
saturated) fat, but low amounts of vegetables, fibers, and 





its may trigger a proinflammatory environment [10] in 
susceptible individuals through an alteration in the gut 
microbiome and a disturbed epithelial barrier function.
Although no guidelines exist advocating a specific diet 
during established disease [11–14], approximately 70% of 
IBD patients assume that diet influence their condition 
[15], nearly 60% of those consider diet to play a major role 
in triggering a relapse [16], and 16% of them are con-
vinced that diet could initiate the disease [17]. Although 
IBD patients are highly interested in nutrition, only 
8–16% are satisfied about the information they receive 
from their physicians [18]. Even half of them never re-
ceived a dietary advice [19]. Interestingly, when trying to 
modify their dietary habits, patients rather focus on 
avoidance of certain foods instead of increasing the intake 
of dietary components with presumably more beneficial 
properties [20]. Specifically, IBD patients report to avoid 
spicy foods, vegetables, fruits, nuts, milk, red meat, soda, 
popcorn, dairy, high-fiber foods, coffee and beans, where-
as an improvement of symptoms is rather attributed to 
banana, rice, and yogurt [21]. Additionally, a population-
based Canadian IBD Cohort could show that IBD pa-
tients may tend to substitute diets high in nutrients with 
sugar-laden beverages [22]. This apprehension may not 
be supportive for IBD patients, but rather fuels the re-
striction of certain foods in IBD patients with subsequent 
considerable impact on social life [17] and the potential 
risk of nutritional deficiencies, including iron, vitamin 
B12, calcium, and vitamin D [23]. This pattern of avoid-
ance of specific food is even more pronounced in patients 
with stricturing Crohn’s disease (CD) [24], rendering 
them a highly vulnerable patient group for deficiencies of 
micronutrients.
In this review, we summarize current knowledge and 
recent data on IBD and nutrition, highlight dietary com-
ponents and their potential to modify course of IBD and 
discuss how to best recognize, treat, and prevent nutrient 
deficiencies in IBD patients.
Nutrition and Risk of IBD
The worldwide rising incidence of IBD [25] is paral-
leled by a “Westernization” of dietary habits in develop-
ing countries. It is therefore obvious that, in addition to a 
genetic influence [26], environmental factors, especially 
diet, undoubtedly play a major role in the development of 
IBD [8, 9, 27].
The exact pathomechanism how diet promotes the de-
velopment of IBD is still unknown, while 2 main mecha-
nistic explanations are most prominent and need to be 
pointed out. First of all, diet has a profound impact on the 
composition of gut microbiota and changes of nutrition-
al composition during early childhood or even later in life 
can favor an anti- or proinflammatory composition [28–
30]. Western diet is associated with a lower microbial di-
versity [31], a higher abundance of Bacteroides and En-
terobacteriaceae [28–30, 32–34], and lower levels of Fir-
micutes [28], whereas a rural diet rather is linked to more 
short-chain fatty acids and a lower abundance of Entero-
bacteriaceae (Shigella and Escherichia) [32]. This change 
in diet in industrialized countries may subsequently shift 
the microbiota composition, which may promote a pro-
inflammatory environment in susceptible patients.
Previous studies showed that patients with IBD have 
a lower diversity in their gut microbiota [35, 36] with an 
increase in invasive Escherichia coli [37], increase in En-
terobacteriaceae family [38], and a reduced proportion 
of the phyla Bacteroidetes and Firmicutes. However, it is 
not clear, whether this dysbiosis represents a primary 
event triggered by a specific diet or is only a conse-
quence of the disease itself.
Second, aside from microbial alterations, diet can also 
alter host immunity through many different mechanisms 
as increased intestinal permeability, decreased level of co-
lonic Treg cells, and increased proinflammatory markers 
[39]. A western diet high in fat and sugar decreased mu-
cus layer thickness, increased intestinal permeability, and 
increased tumor necrosis factor α secretion in susceptible 
mice [40].
There are many potential candidates being responsible 
for inducing an inflammatory reaction within the gut. 
Next to protein, lipids, and carbohydrates, also micropar-
ticles and food chemicals like emulsifiers or thickeners 
can contribute to intestinal and potentially subsequent 
systemic inflammation.
Interestingly, food additives, such as emulsifiers, may 
simultaneously act on both of the 2 aforementioned 
mechanisms [41], which will also be eluded below.
Breastfeeding
The first nutrient a human being receives either repre-
sents breast milk or formula feeding. The microbiota of 
infants who are breastfed differ from those who are for-
mula fed [42], and nearly 30% of the bacteria within the gut 
derive from breast milk [43]. These early perturbations in 
the microbiome through diet can potentially increase the 
risk for disease. In the last decades, there has been a de-
crease in breastfeeding [43] and an increase in IBD [25]. 
Although this inverse association has not been investigated 
Nutrition in IBD 3Digestion
DOI: 10.1159/000505368
systematically yet, it certainly represents an interesting ob-
servation that should be further considered. Furthermore, 
many studies confirm a protective effect against future IBD 
development in breastfed infants [44, 45], whereas the 
strongest decrease in risk appears in children fed up to 12 
months [46]. Aside from a decreased risk in developing 
IBD, a history of breastfeeding is inversely associated with 
a more favorable course in children having CD [47].
Fat
The intake of omega-6 (n-6) and omega-3 (n-3) poly-
unsaturated fatty acids (PUFAs) are among the most in-
vestigated nutrients with a potential association to IBD. 
n-6, respectively n-3, means that the last double bond is 
6, respectively 3, carbon atoms away from the carboxyl 
end of the polyunsaturated carbon chain of fatty acid. N-6 
PUFAs (linoleic acid [LA], arachidonic acid) are precur-
sors to eicosanoids that are proinflammatory, whereas 
n-3 PUFAs (docosahexaenoic [DHA], eicosapentenoid 
and alpha-LA [ALA]) are precursors to eicosanoids be-
lieved to be anti-inflammatory [48]. LA and ALA are both 
essential fatty acids and thus have to be ingested, since the 
human body is not able to synthesize them. In sunflower 
oil as well as many other plant-based oils and margarine, 
high amounts of n-6 can be found. In contrary, n-3 can 
be found in high amounts in fatty fish and cod liver oil 
(DHA/eicosapentenoid) and also linseed oil and green 
leafy vegetables (ALA). The change of dietary habits in 
westernized countries is characterized by a rise of the n-
6/n-3 ratio [49]. 
One of the first epidemiological studies investigating 
dietary factors and the increase in IBD in Asian countries 
is a Japanese study that could demonstrate an association 
of an increased n-6/n-3 ratio and a correlation to an in-
creased incidence of CD [50]. A prospective cohort study 
[51] revealed a 2-fold increased risk of developing ulcer-
ative colitis (UC) in patients with high intake of the n-6 
PUFA LA. Furthermore, this study showed a 77% risk 
reduction in developing UC in patients with highest di-
etary intake of DHA acid, a n-3 PUFA. No decreased UC 
risk in patients eating high amounts of ALA could be 
demonstrated. Similar to the majority of studies on nutri-
tional intake in IBD, no conclusions can be drawn about 
the causality of the results because of the study design. 
Another case-control study in Canadian children with 
CD demonstrated similar results with a lower risk for CD 
in children with a higher ratio of n-3/n-6 fatty acids [52]. 
The protective effect of n-3 fatty acids appears to apply 
not only in children but also in the adult population over 
45 years [53]. In this cohort, total dietary n-3 intake, es-
pecially docosahexanaenoic acid, was negatively associ-
ated with the development of UC.
These results find support in the prospective Nurses’ 
Health Study cohort, where a higher long-term intake of 
n-3 PUFA was associated with a lower risk, and the high-
er intake of trans-unsaturated fatty acids was associated 
with an increased risk of UC [54].
However, a newer meta-analysis on this subject sug-
gests a lack of association between fat intake and UC risk 
[55]. On the other hand, and in contrast to many other 
studies indicating n-3 PUFA as a protective dietary factor 
regarding IBD risk, a small Japanese case-control study 
found a positive association of n-3 PUFA and CD risk. 
The authors argue that the intake of oily fish high in n-3 
PUFA would also necessarily increase fat intake as a 
whole and therefore potentially increase the risk of IBD 
[56].
To sum up, the currently available data are rather 
controversial, with most of the studies indicating an in-
creasing risk of IBD with higher amounts of n-6 (or 
 n-6/n-3 quotient, respectively) PUFAs and a possible 
protective effect of n-3 PUFA [54, 57]. One hypothesis 
of the inhomogeneous study results regarding fatty acids 
could be interindividual differences in the metabolism 
of n-3 and n-6 PUFA. Since dietary fatty acids are me-
tabolized through enzymes that are genetically regulat-
ed, a genetic polymorphism at the CYP4F3 locus could 
modify dietary n-3 and n-6 PUFA beneficially in UC 
patients [58]. 
Proteins
Dietary proteins are derived from many different 
foods and can be classified into plant-based and animal-
based protein sources. Evidently, considering the role of 
proteins in the diet, one has to distinguish between ani-
mal and vegetable proteins because animal-based protein 
sources often consist of more saturated fat than plant-
based protein. In the epidemiological analysis of Shoda et 
al. [50], high intake of animal protein was the strongest 
independent risk factor for an increased incidence of CD. 
These findings are confirmed by a recently published pro-
spective study (The E3N Prospective Study) conducted in 
French middle-aged women [59]. Like in the Japanese 
study, the positive association between protein intake and 
the risk of IBD was only seen with regard to animal but 
not vegetable protein. Other smaller studies and case-
control series did show a trend toward a higher risk of 
IBD in patients, but without statistical significance [60].
However, meat consumption, as a high source of ani-





meta-analysis, but this association is ambiguous due to 
methodological flaws in the included studies [61]. Inter-
estingly, the association of higher risk of IBD could also 
be demonstrated in high consumption of fish, another 
source of animal proteins [59, 60].
Carbohydrates
Although the data are inconclusive, most studies show 
a positive association between high intake of refined sug-
ar and the development of CD [56, 62], but not UC [56, 
60]. However, in UC high intake of sucrose, a subtype of 
carbohydrates may be associated with a higher risk [63]. 
Despite recently published data [64, 65] showing an in-
creased risk of UC in patients following a dietary pattern 
high in sugar and sweetened beverages, these findings 
could not be confirmed by data from 2 large prospective 
cohort studies from Sweden [66], in which a lack of an 
association between IBD and sweetened beverages could 
be demonstrated. However, this study did not distinguish 
between various artificial sweeteners, such as sucralose, 
saccharin, aspartame, cyclamate, and other sweeteners. 
Thus, it still remains possible that distinctive artificial 
sweeteners may promote the risk for IBD. 
Opposed to the possible negative effect of sugars in 
general, fruits and vegetables, also rich in carbohydrates, 
may reduce the risk for CD, but not UC [52, 60, 67]. Spe-
cifically, many studies analyzed dietary fiber, which is 
found in high amounts not only in fruits and vegetables 
but also in whole grain and legumes. In a large prospec-
tive study, long-term intake of fiber, particularly from 
fruits and in a smaller part of vegetables, reduced the risk 
for CD, but not for UC. In the group with the highest in-
take (24.3 g/day), there was a 40% lower risk for CD [68]. 
A meta-analysis could observe a significant dose – re-
sponse relationship between fiber intake and CD risk 
with an decreasing risk of 13% for every 10 g/day incre-
ment in fiber intake [69]. Interestingly, fiber intake from 
whole grain or legumes had no effect on the risk for IBD 
[68]. Another US study showed that patients with great 
intake of fruits, vegetables, and fish had a 53% lower risk 
of CD [70].
Another population-based prospective cohort study 
in Europe (EPIC-IBD) [71] supported the negative as-
sociation of fiber intake and UC. In contrary to the US 
data of Ananthakrishnan et al. [68] showing a reduced 
risk for CD in higher amounts of fiber intake, there was 
no association seen in the EPIC-IBD study. However, it 
has to be mentioned that other nutrients in vegetables 
or fruits may be responsible for reducing the IBD risk 
[63].
Other Nutrients
While vitamin D deficiency is highly prevalent in pa-
tients with established IBD [72], women with high 25-hy-
droxyvitamin D levels (25[OH]D) were shown to have a 
significantly lower risk reduction for developing CD. For 
each 1 ng/mL increase in 25(OH)D plasma level, there 
could be shown a significant relative risk reduction of 6% 
for CD and a nonsignificant relative risk reduction of 4% 
for UC [73]. Another large observational trial (EPIC) did 
not show an association between prediagnostic 25(OH)D 
concentrations and the development of CD or UC [74].
Polyphenol with its classes flavonoids (flavonols, fla-
vones, isoflavones, flavanones, anthrocyanidins, and fla-
vanols), stilbenes (resveratrol), phenolic acids, and lig-
nans have anti-inflammatory properties by ameliorating 
oxidative stress. Despite the potential positive mecha-
nism, the EPIC cohort study [75] could not show a nega-
tive association of developing CD or UC and dietary poly-
phenol intake. Interestingly, flavones, abundant in thyme, 
rosemary and oregano, and resveratrol, present in grapes 
and wines, were associated with a lower risk for CD.
In summary, data of macronutrients and IBD risk are 
very inconclusive, but it can be highlighted that a western 
diet has a higher risk for IBD [60, 76], and specifically a 
diet with a high n-3/n-6 fatty acid ratio, rich in fruits and 
vegetables, reduces the risk of IBD. These statements find 
support in the latest ESPEN Guidelines [11].
Diet and Course of Disease
Although the association of diet and the development 
of IBD are highly interesting from an epidemiological and 
pathophysiological point of view, patients with an estab-
lished diagnosis of IBD are interested in counseling on 
dietary modification aiming at ameliorating their disease 
course. Due to a lack of robust evidence, neither the 
ECCO, AGA, nor the ESPEN Guidelines recommend any 
specific diet during remission or active disease. A recent-
ly published Cochrane analysis concludes that an effect of 
any dietary interventions on CD or UC is uncertain [77]. 
Therefore, physicians are reluctant to provide any spe-
cific recommendations. Subsequently, the majority of pa-
tients continue their seek of dietary advice in various 
sources, including the Internet [78], where the quality 
and evidence basis of advice received hardly can surpass 
physician-based counseling. Thus, it is crucial that physi-
cians are capable of providing certain dietary recommen-
dations to patients and give orientation in the best pos-
sible way despite the clear-cut limitation of data. Three 
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quarters of patients avoid – presumably unnecessary in 
the majority of instances – certain foods during remission 
to prevent a flare [16]. Even more patients avoid some 
food groups, especially proteins and fat, during flares due 
to fear of worsening symptoms [19, 79].
Regarding dietary modification, patients can either 
omit certain foods (elimination or exclusion diets) or add 
specific nutrients to the diet. It is crucial to differentiate 
between diets that may induce or maintain remission and 
consequently impact the course of disease and diets that 
only alleviate symptoms of IBD patients.
Elimination/Exclusion Diets
To explain the effect of exclusive diets, various mecha-
nisms are currently being discussed. Some of the hypoth-
eses feature a direct relationship between diet and IBD. 
For example, it has been suggested that diet can directly 
alter the composition of the microbiome. Other mecha-
nisms suggest that dietary antigens trigger an immune 
response and finally diet influences the production of me-
tabolites by the microorganisms living in the gut, which 
could have an impact on the mucus layer and the immune 
response [80].
Exclusive enteral nutrition (EEN) is the only really es-
tablished diet in IBD patients, specifically in pediatric CD 
patients [81, 82]. Enteral nutrition, classified as elemental 
(based on amino acids, sugars, fats, vitamins, and miner-
als) or nonelemental (composed of oligopeptide or whole-
protein sources), is a liquid diet given by mouth or by 
feeding tube. Due to remission rates up to 80% in pediat-
ric CD patients [83–85] following 6–8 weeks of EEN and 
a better efficacy and higher mucosal healing rates than 
corticosteroids [86], exclusion diet is considered as first-
line treatment option in children with active luminal CD 
[87]. Similar remission rates can be achieved regardless of 
whether elemental or nonelemental regimens are used 
[81]. In adult CD patients, EEN is less effective than cor-
ticosteroids in inducing remission [81]. Furthermore, its 
poor palatability is the main reason for an exceedingly 
rare use in the adult population, and ECCO does not rec-
ommend EEN as therapy for inducing remission in adult 
CD patients [13]. However, in contrast to Europe, in Ja-
pan, EEN is used as primary therapy in adult CD patients 
[88] due to a Japanese study demonstrating higher rate of 
inducing remission and a better safety profile [89].
Due to the fact that partial enteral nutrition (PEN; only 
50% elemental formula) reduces markedly the efficacy of 
inducing remission [90], the exclusion of all nutritional 
components representing a regular diet is probably the 
main mode of action in EEN.
There are insufficient data to use EEN as a mainte-
nance therapy in adult or pediatric quiescent CD patients 
[91]. However, a small Japanese randomized-controlled 
trial showed a lower relapse rate in patients assigned to a 
half elemental diet than that in the free diet group (34.6 
vs. 64.0%, multivariate hazard ratio 0.4) [92]. Addition-
ally, there exists no indication in treating UC patients 
with EEN.
The Crohn’s Disease Exclusion Diet (CDED) consists 
of a reduced intake of animal and saturated fat, gluten-
containing grains, and emulsifiers, and an increase in 
fruits, vegetables, and resistant starch. Fifty percent of nu-
trition will be given as PEN. The reduction of dietary 
components is the most important mechanism, with al-
lowed nutrients serving to reduce possible nutrient defi-
ciencies and improve dysbiosis. The first study investigat-
ing CDED confirmed its effectiveness for the induction 
of remission in children with CD [93]. A further study 
demonstrated an induction of remission even for chil-
dren failing biological therapy [94]. The data of the first 
randomized controlled study comparing CDED plus 
PEN versus EEN over 12 weeks in pediatric CD patients 
demonstrated similar response and remission rates by 
week 6 and sustained remission by week 12 [95]. Due to 
the easier treatment approach with the same efficacy, 
CDED has the potential to change the dietary recommen-
dation in the future. There is an ongoing study with adult 
CD patients following CDED [96].
A novel diet, called CD-TREAT diet, tries to mimic 
EEN with an ordinary food diet, based on the composi-
tion of EEN [97]. The diet excludes specific components 
like gluten and lactose and is low in fibers. The advantage 
of the CD-TREAT diet to EEN is the palatability that is 
the limiting factor of EEN in adults. The study demon-
strated a better tolerance of CD-TREAT in a healthy pop-
ulation and induced a similar effect to EEN on the fecal 
microbiome. After 8 weeks of CD-TREAT diet, 80% (4/5) 
showed a clinical response and 60% (3/5) of the pediatric 
CD patients were in remission. A limitation certainly is 
the low number of only 5 active pediatric CD patients. 
Nevertheless, this novel approach in creating a diet based 
on the established EEN is interesting and has the potential 
to influence further dietary interventions.
The specific carbohydrate diet (SCD) is based on an 
exclusion of complex carbohydrates and processed foods. 
Monosaccharides, chicken, fish, and hard cheese are al-
lowed. It is believed that complex carbohydrates are poor-
ly absorbed in the intestinal tract and therefore result in 
inflammation. Only case series and small retrospective 





tients, a symptomatic improvement could be demon-
strated [98] as well as a mucosal improvement [99]. An-
other uncontrolled study showed a lack of mucosal heal-
ing with SCD in asymptomatic children with CD [100]. 
Recently, a small prospective study with 12 pediatric CD 
patients showed an improvement in clinical and labora-
tory parameters and changes in the fecal microbiome 
[101]. In adult patients, a clinical benefit could be shown 
through an online survey [102] and a case series of pa-
tients in remission following an SCD [103]. No studies in 
adults investigated laboratory or mucosal improvement.
Vegetarian diet is thought to presumably downregu-
late inflammation, whereas the western diet is proinflam-
matory and leads to dysbiosis [104]. Around 4% of IBD 
patients follow a vegetarian diet [19, 105], whereas 17% 
of them restrict their diet due to belief of a benefit for their 
IBD [105]. A prospective cohort study investigating di-
etary factors in UC patients in remission could demon-
strate that a higher intake of meat, particularly red meat, 
could increase the risk of a relapse in UC [106]. A Japa-
nese study with 22 CD patients in remission showed after 
2 years a higher maintenance of remission in the semi-
vegetarian diet (94%) than in the omnivorous group 
(33%). The semi-vegetarian diet consisted of a lacto-ovo-
vegetarian diet with once-weekly fish and meat once ev-
ery 2 weeks [107]. However, a cross-sectional analysis in 
Swiss IBD patients did not find an association of vegetar-
ian diet and the course of IBD [105]. In a recently pub-
lished prospective randomized trial (Food and Crohn’s 
Exacerbation Study) [108], a reduced consumption of red 
meat and processed meat did not reduce the risk of symp-
tomatic CD relapse in patients in remission. In addition, 
calprotectin was measured in a subset of patients, which 
showed no difference between the 2 groups.
Aside from a lower intake of protein or fat, vegetarians 
normally eat more vegetables and fibers than omnivores. 
In a mouse model, dietary fat induced colitis in interleu-
kin-10-deficient mice, so that the authors conclude that 
certain fats may in genetically susceptible hosts promote 
IBD [109]. A recently published prospective study in UC 
patients found a 3-fold increased risk of flare in patients 
consuming specific fatty acids like myristic acid (con-
tained in palm and coconut oil and dairy fat) as well as in 
patients consuming ALA [110]. This finding may appear 
surprising as ALA belongs to the n-3 PUFA, which are 
thought to act anti-inflammatory [48]. However, there 
exists only one study showing a positive effect of n-3 
PUFA regarding the course of disease in IBD. In patients 
with CD, a fish-oil preparation containing a high dose of 
n-3 PUFA reduced the risk of a flare compared to patients 
receiving placebo capsules significantly with a 33% abso-
lute reduction (28 vs. 69%, p < 0.001) [111]. The results of 
this study were questioned because of the small sample 
size (78 patients). In a larger multicenter trial (EPIC-1 
and EPIC-2) with > 1,000 patients with CD n-3 PUFA did 
not reduce the risk of a flare over 1 year of follow-up 
[112]. A recently performed meta-analysis came to the 
same results as the EPIC studies, namely, that in IBD n-3 
PUFAs have, despite the anti-inflammatory effect within 
the gut [113], no effect in maintaining remission [114].
A study by Llewellyn et al. [115] examined over 30 dif-
ferent diets in mice and demonstrated that a high-protein 
diet exacerbates colitis in mice and dietary psyllium, a 
specific fiber, ameliorated colitis, was associated with an 
increased bacterial diversity and reduced intestinal per-
meability. The authors propose that in mild to moderate 
IBD, a diet low in protein and high in selectively benefi-
cial fiber could improve intestinal barrier function and 
reduce the microbial load. Furthermore, a study by Broth-
erton et al. [116] demonstrated a 40% reduced flare risk 
in patients with CD who did not avoid fiber than in pa-
tients who avoided high-fiber diet. In UC, no difference 
could be shown. Patients with UC consumed more fibers 
than patients with CD; especially, female CD patients and 
CD patients with prior surgery and hospitalization con-
sumed significantly less fibers. This may partly be due to 
conscious avoidance of fibers by CD patients with stric-
tures due to fear of obstructive symptoms or because of 
recommendation of their treating physician. These re-
sults are in contrast to a systematic review conducted by 
Wedlake et al. [117], in which no effect of inducing remis-
sion or avoidance of flare regarding fiber intake in pa-
tients with CD could be shown. Avoidance of dietary fi-
bers during a disease relapse represents a generally ac-
cepted recommendation [118]. Interestingly, a recently 
published trial investigating the risk for pouchitis and 
fruit consumption [119], a source high in fibers, could 
show a lower rate of pouchitis in UC patients consuming 
high intake of fruits. Furthermore, a higher microbial di-
versity in patients with high fruit consumption was found.
The Paleo diet, also referred to as the “Stone Age diet,” 
is based on the concept that the nutrition of our ancestors 
was more natural and therefore healthier. It contains veg-
etables, fruits, nuts, seeds, small fish/shellfish, lean small 
game meat, and avoidance of processed foods [120]. An 
extension of the Paleo diet is the autoimmune protocol 
diet in IBD. This diet was investigated in an open-labeled 
uncontrolled trial with no improvement in inflammatory 
markers, but an amelioration of symptoms and a mainte-
nance of remission in all 11 patients [121].
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A similar anti-inflammatory diet with avoidance of 
lactose and processed complex carbohydrates, a higher 
intake of soluble fiber, leeks, onions, and fermented foods 
(pre- and probiotics), and a modified fat intake has been 
demonstrated to ameliorate symptoms in IBD patients in 
case series [122].
Although a Mediterranean diet is known to have ben-
eficial effects on multiple chronic diseases [123, 124], 
with anti-inflammatory effects [125] and microbiota-
modifying properties in CD patients [126], no random-
ized trial yet has systematically addressed Mediterranean 
diet in IBD. However, a randomized trial in UC patients 
is currently ongoing [127].
Fermentable, oligo-, di-, mono-saccharides, and poly-
ols (FODMAPs) are poorly absorbed short-chain carbo-
hydrates that may trigger abdominal bloating, abdominal 
pain, wind, and diarrhea. IBS-like symptoms are com-
mon in IBD and affect around 39% and are more com-
mon in CD than in UC [128], and differentiating these 
symptoms to inflammation-related pain can be cumber-
some and difficult.
A reduction of FODMAPs improved abdominal pain, 
bloating, and diarrhea in around a half of IBD patients 
[129]. Furthermore, a randomized, double-blind, place-
bo-controlled study in patients with IBD and IBS showed 
greater severity of pain, bloating, flatulence, and fecal ur-
gency in patients consuming FODMAPs [130]. It is im-
portant to mention that a diet low in FODMAPs may im-
prove symptoms in IBD patients but does not affect the 
inflammatory activity.
Interestingly, gluten-free diet is followed by around 5% 
[105, 131, 132] of IBD patients without celiac disease that 
is more than the double compared to the general popula-
tion [132]. Almost half of the patients believe that this diet 
has a beneficial effect on their disease [105], although 
there are no studies showing that the inflammation would 
be positively influenced other than a clinical improvement 
[131]. Furthermore, the amelioration of abdominal symp-
toms in nonceliac gluten sensitivity presumably is more 
related to the avoidance of fructan rather than gluten 
[133], so that a low FODMAP diet seems to have a higher 
impact regarding symptoms than a gluten-free diet.
To complicate this topic even further, emulsifiers are 
used in many diets that could alter the gut microbiota and 
promote colitis [41, 134]. This effect appears to be direct-
ly related to a microbiota-modulating property of some 
emulsifiers, as in unexposed mice undergoing fecal mi-
crobiota transplantation with stool from previously ex-
posed mice, alterations in mucosal barrier could be in-
duced. Titanium dioxide nanoparticles contained in 
pharmaceutical products represent another food addi-
tive, which has been shown to promote intestinal inflam-
mation in dextran sodium sulfate colitis in mice [135]. 
Furthermore, splena, an artificial sweetener consisting of 
sucralose maltodextrin, promotes in CD-prone mice an 
alteration of the microbiome with E. coli overgrowth and 
increase of Proteobacteria what consecutively resulted in 
elevated myeloperoxidase activity and increased inflam-
mation and gut damage [136].
We can summarize that there exist several dietary op-
tions to influence symptoms in IBD patients and diets 
that may alter the course of IBD. Patients who are inter-
ested in a special diet should, however, be advised by an 
IBD specialist or dietician due to the risk of malnourish-
ment or nutritional deficiencies.
Dietary Supplements
ECCO’s topical review on complementary medicine 
and psychotherapy in IBD [137] concludes that there is 
insufficient evidence to support the use of vitamins to in-
duce or maintain remission in CD and UC.
Nevertheless, a prospective cohort study demonstrat-
ed that UC patients with 25(OH)D levels below 35 ng/mL 
had a higher risk of clinical relapse (OR 1.25, 95% CI 
1.01–1.56, p = 0.044) [138].
In CD patients, 25(OH)D concentration is inversely 
associated with disease activity [139], and in UC patients, 
25(OH)D concentration is inversely associated with mu-
cosal inflammation [140]. Moreover, a longitudinal study 
demonstrated higher morbidity and disease severity in 
patients with low 25(OH)D levels [141].
Furthermore, oral supplementation with 1,200 IE vita-
min D3 reduced the risk of relapse in CD patients insig-
nificantly from 29 to 13% (p = 0.06) [142]. Another study 
showed similar results, in which the quality-of-life scores 
improved and the CDAI score decreased after vitamin D 
supplementation, but there were no significant changes 
in laboratory or cytokine measures [143]. Additionally, a 
vitamin D substitution with 40,000 units cholecalciferol 
weekly for 8 weeks in active UC patients reduced intesti-
nal inflammation and increased the abundance of Entero-
bacteriaceae without altering the fecal bacterial composi-
tion [144].
Although the data are not very robust, supplementing 
vitamin D is safe and well tolerated, so that it should be 
given to all IBD patients with vitamin D deficiency [145].
Anthocyanins, which occur in high amounts in blue-
berries and black raspberries, have anti-inflammatory 
and antioxidative effects [146]. An open pilot trial dem-





berry preparation in mild to moderate UC patients 
achieved remission and response in 63.7 and 90.9%, re-
spectively, after 6 weeks. Additionally, goji berry, another 
traditional supplement, has been shown to promote bu-
tyrate-producing bacteria and Bifidobacteria in interleu-
kin-10-deficient mice, which in turn results in the sup-
pression of intestinal inflammation [147]. 
Another trial investigating antioxidative properties 
could demonstrate a significant reduction of oxidative 
stress in CD patients receiving vitamin E and C supple-
mentation. However, disease activity remained stable 
[148]. Aloe vera, an herbal preparation with potential an-
ti-inflammatory effects in vitro [149], showed a signifi-
cant clinical response compared to placebo (47 vs. 14%, 
p  < 0.05) in a double-blind, randomized, placebo-con-
trolled trial but no significance in terms of clinical remis-
sion (30 vs. 7%, p = 0.09) or improvement (37 vs. 7%, p = 
0.06) after 4 weeks [150]. Another antioxidant is querce-
tin, a flavonoid that is present in vegetables and fruits. 
Quercetin could ameliorate colitis in mice by inducing 
anti-inflammatory effects of macrophages and could re-
store hemostasis of the microbiota in colitic mice [151]. 
This interesting approach should be further studied.
A further herbal treatment consisting of myrrh, cham-
omile blossom extract, and coffeae carbo was studied in a 
randomized double-blind trial in quiescent UC patients 
compared to mesalamine [152]. The relapse rates after 12 
months did not differ between the 2 groups, rendering the 
German Society for Digestive and Metabolic Diseases to 
advocate its use as complementary treatment in UC 
maintenance therapy [153].
Curcumin, a polyphenol derived from the Indian spice 
turmeric (Curcuma longa), is used in traditional Chinese 
medicine and in ayurvedic medicine because of its anti-
inflammatory and antioxidative properties [154, 155]. In 
a randomized, placebo-controlled, double-blind study, 
curcumin in a dose of 3 g daily was more effective than 
placebo in inducing clinical remission and response in 
mild to moderately active UC despite maximal mesala-
mine treatment (53.8 vs. 0%, p = 0.01 and 65.3 vs. 12.5%, 
p < 0.001, respectively) [156]. All patients continued their 
optimal mesalamine medication. The study has been crit-
icized for not adequately being blinded because of the po-
tential smell and taste of curcumin [157]. Besides an effect 
in inducing remission, curcumin has been shown, even in 
a lower dose of 2 g daily, to maintain patients with quies-
cent UC in remission [158]. In this randomized, double-
blind, placebo-controlled trial, only 4.7% patients who 
received curcumin relapsed during 6 months of therapy 
compared to 20.5% in the placebo group (p = 0.04). There 
were no serious side effects. Furthermore, curcumin may 
be effective as enema in UC patients. In a pilot study, pa-
tients receiving curcumin enema had higher clinical re-
sponse (92.9 vs. 50%, p = 0.01) and were significantly 
more in remission (71.4 vs. 31.3%, p = 0.03) than patients 
receiving placebo enemas (significant only in the per-
protocol analysis). A Cochrane analysis supports the 
finding that curcumin is effective in the maintenance of 
remission in UC [159].
For the daily use of curcumin, 2 important facts have 
to be mentioned. First, the acceptable daily intake evalu-
ated by the FAO/WHO Expert Committee on Food Ad-
ditives (JEFCA) [160] is 0–3 mg/kg bodyweight, being 
considerably lower than the doses used in the studies. Sec-
ond, due to the fact that curcumin is not labeled as a med-
ication and only available as over-the-counter food sup-
plement, it is often not available in pure forms and con-
tains numerous additives. Those capsules frequently 
available represent turmeric capsules with around 50 mg 
of curcumin and piperine, which will enhance serum con-
centration of curcumin [161]. This makes it very difficult 
to achieve the high doses used in the studies.
Plantago ovate (Psyllium) is a dietary fiber indigenous 
to Mediterranean region and India and used as herbal 
medicine [162]. In an open-label trial with 105 UC pa-
tients in remission, subjects were randomized in groups 
receiving Plantago ovata seeds (10 g b.i.d.), mesalamine 
(500 mg i.d.), or Plantago ovate seeds plus mesalamine 
[163]. There was no difference in maintenance of remis-
sion between the groups, so that the authors concluded 
that Plantago ovata might be as effective as mesalamine 
to maintain remission in UC. Furthermore, the fecal bu-
tyrate level was significantly increased in patients who re-
ceived Plantago ovata. 
Malnutrition
Patients with active IBD are at an increased risk of mal-
nutrition. The prevalence of malnutrition in IBD ranges 
between 6 and 16%, representing a 5-fold increase in risk 
for malnutrition as compared to non-IBD subjects [164, 
16]. Regardless of the proper definition used for malnu-
trition, the high prevalence calls for a more profound 
consideration of this complication among healthcare 
professionals. Unjustified bowel rest during hospitaliza-
tion may further worsen the situation in UC patients 
[165]. History of surgery due to IBD doubles the risk for 
malnutrition, while ongoing clinical activity and avoid-
ance of some food groups during a flare is associated with 
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a 4- and even 10-fold higher malnutrition risk, respec-
tively [16]. Therefore, the highest impact on malnutrition 
probably is derived by food-restrictive behavior and de-
creased appetite during flare.
The most common micronutrient deficiencies in de-
scending order are iron, vitamin D, vitamin B12, zinc, 
and folic acid deficiency. Cause of micronutrient defi-
ciencies are multifactorial and include a restricted food 
intake, enteric loss of vitamins, malabsorption, and unde-
sirable effects of some medication [166]. 
Iron Deficiency
Prevalence of iron deficiency (ID) can be seen in up to 
70% and is the most common reason for anemia in IBD 
patients (ID anemia [IDA]). The second most common 
cause of anemia in IBD patients is anemia of chronic dis-
ease (ACD) and often co-exists in IBD patients with ID. 
ID in IBD patients is multifactorial and results from a de-
creased intake of iron, an impaired iron uptake in the du-
odenum and upper jejunum, decreased iron resorption 
due to high hepcidin levels, and chronic blood loss from 
the inflamed mucosa [167]. Furthermore, in CD, low BMI 
and nonsmoker are positively associated with IDA [168].
Diagnosing IDA in IBD patients can be difficult due to 
the overlap of ACD in many patients. Normally, a ferritin 
< 30 μg/L is unequivocally diagnostic for an ID, whether 
with or without anemia. As ferritin acts as an acute-phase 
reactant in inflammatory states, as well as in obesity, age, 
and liver disorders, ferritin level rise and can therefore 
mask ID. However, ferritin levels > 100 μg/L exclude an ID 
even in states of inflammation [169, 170]. In cases of fer-
ritin values between 30 and 100 μg/L with elevated CRP, 
transferrin saturation can be measured. A transferrin sat-
uration < 20% implies an absolute or functional ID. Abso-
lute ID is defined as transferrin saturation < 20% with a 
ferritin < 100 μg/L and functional ID (major component 
of ACD) as transferrin saturation < 20% in combination 
with ferritin concentrations of 100–299 μg/L [171, 172]. 
In treating iron-deficient IBD patients, some aspects 
have to be considered. The well-known Ganzoni formula 
underestimates iron requirement in IBD patients, why a 
new simplified and more accurate dosage scheme for IBD 
was evolved (FERGIcor) [173]. 
The widely used oral iron supplements consist of iron 
salts (iron sulfate, fumarate, and gluconate), and the ab-
sorption of nonheme iron is poor. The duodenum can 
maximally absorb 10–20 mg of iron per day and around 
90% is not absorbed [174]. Therefore, high doses are often 
administered, what may lead to ROS-mediated toxicity of 
nonabsorbed iron on intestinal mucosa [175]. Further-
more, oral iron can reduce Lactobacillus and Bifidobacte-
rium bacteria and increase abundance of Enterobacteria-
cea [176] and subsequently lead to gut dysbiosis and in-
crease inflammation and diarrhea [177, 178]. Other small 
studies confirmed the potential of an increased clinical 
disease activity in IBD patients after oral ferrous fumarate 
[179] and a small, but in our opinion, a relevant chance 
of having a relapse of 6% [180]. 
Due to the abovementioned concerns and high rates of 
gastrointestinal intolerability to oral ferrous iron, a novel 
oral iron comprising a stable complex of ferric iron with 
maltol, namely, ferric maltol, has been tested in IBD pa-
tients in a Phase 3 trial [181]. The Phase 3 extension trial 
confirmed the tolerability of ferric maltol [182].
Nevertheless, oral iron cannot be completely aban-
doned in IBD patients, but it has to be kept in mind that 
high doses of oral iron should be avoided in IBD patients, 
especially in some general vitamin supplements. If given 
orally, iron should be administered on alternate days in 
low single doses to optimize iron absorption [183].
Due to high hepcidin level resulting from inflamma-
tion [184], oral resorption of iron may be severely hin-
dered or even be impossible in active IBD patients. There-
fore, ECCO recommends intravenous iron in clinically 
active patients, in patients with intolerance to oral iron, 
or those in need of erythropoiesis-stimulating agents and 
in case of hemoglobin levels below 10 g/dL (due to much 
faster response of intravenous iron) [185].
Administration of intravenous iron may increase the 
risk of infection to around 33% compared to oral or no 
iron [186]. Therefore, in patients with ongoing infection, 
intravenous iron therapy should be only given after care-
ful risk versus benefit consideration due to a fear of exac-
erbating the infection [187].
After correction of ID, every patient should control 
iron levels every 3 months for at least 1 year, and if ferritin 
drops below 100 μg/L, iron should be substituted [185]. 
Patients with active disease should be screened every 
3  months and patients in clinical remission every 12 
months regardless of anemia or not [188].
Vitamin B12 Deficiency
The prevalence of vitamin B12 ranges between 6 and 
38% [189] due to different diagnostic methods used. A 
true vitamin B12 deficiency in asymptomatic patients is 
defined as a serum cobalamin < 148 pmol/L (200 ng/L) 
and an elevated serum homocystein or methylmalonic 
acid [190]. In the duodenum, dietary cobalamin binds in-
trinsic factor, synthesized by the parietal cells, for its ab-





the entire gastrointestinal tract, a vitamin B12 deficiency 
is much more frequent in CD than in UC patients [168]. 
The main risk factor for vitamin B12 deficiency is an ileal 
resection > 30 cm [189]. Interestingly, despite being the 
main site of cobalamin absorption, an ileal CD is not a 
risk factor for a cobalamin deficiency [189]. A well-con-
ducted prospective observational study in which besides 
cobalamin also methylmalonic acid was measured could 
demonstrate that a true vitamin B12 deficiency is very 
rare (3% in CD and 3.3% in UC). Normally, UC patients 
have a vitamin B12 deficiency in a similar frequency as 
the general population. An exception is UC patients with 
ileo-anal J-pouch that may suffer of a vitamin B12 defi-
ciency, probably due a small bacterial overgrowth [192]. 
Anecdotally, after many years of backwash ileitis, a vita-
min B12 deficiency could result. However, this has never 
been investigated.
Vitamin D Deficiency
Up to 60% of IBD patients have a vitamin D deficiency, 
especially patients diagnosed with CD and an increased 
disease activity [72, 193, 194] or pregnant women with 
IBD [195]. Interestingly, young male patients have a very 
high risk [141] and CD patients with isolated colonic in-
volvement or UC patients had a similar prevalence of 
25(OH)D levels compared to CD patients with ileocolon-
ic or small bowel disease [141]. Additionally, a meta-anal-
ysis could demonstrate a higher prevalence of vitamin D 
deficiency in patients with IBD compared to healthy pa-
tients [196]. The underlying reasons for vitamin D defi-
ciency in IBD are multifactorial. There are 2 natural 
sources of vitamin D, namely, ergocalciferol (vitamin 
D2), being present in food, especially in fatty fish and 
mushrooms, and vitamin D3 synthesized in the epider-
mis of the skin upon UVB irradiation [197]. Since in most 
northern countries vitamin D deficiency is a common 
problem in the general population, malabsorption of vi-
tamin D is probably not a major causative factor for the 
vitamin D deficiency in IBD. Rather, patients with IBD 
have an insufficient exposure of sun and the inflamma-
tion upregulates cytokines that subsequently reduce the 
serum 25(OH)D level [197].
Although the data regarding a potential benefit for the 
course of disease in IBD are inconclusive, vitamin D is 
important to bone health. Especially in patients with IBD, 
who probably needs repetitively corticosteroids, low 
25(OH)D levels should be avoided. Since adherence is an 
important limitation in patients with chronic diseases, a 
practical approach to substitute vitamin D is giving them 
1 monthly 45,000 IU.
Zinc Deficiency
Zinc is a trace element found in high amounts in food 
of animal origin, especially in oysters and beef [198]. It is 
not surprising that vegetarian have much more often a 
zinc deficiency than omnivores [199]. Due to the fact that 
zinc is absorbed in the small intestine and the main route 
of zinc losses are endogenous intestinal losses with up to 
12 mg zinc loss in patients with a stoma [200, 201], pa-
tients with malabsorption are prone to zinc deficiency. In 
a Korean study, zinc deficiency could be demonstrated in 
38.5% of IBD patients [202]. Likewise, around 65% of CD 
patients in remission were found to have zinc levels below 
the reference value despite a higher intake than the con-
trols [203]. In children with CD, zinc deficiency is not 
very frequent but higher than in the healthy controls 
[204]. The low zinc values are associated with an in-
creased risk for hospitalization, surgery, and complica-
tion in CD and UC [205], and normalization of zinc de-
ficiency was associated with these outcomes [205]. Al-
though low zinc levels did not predict a complicated 
disease course in the Swiss IBD Cohort, it was associated 
with depressive symptoms in multivariate analysis [206]. 
However, serum zinc levels are notoriously difficult to 
interpret because inflammation, collection time during 
the day, age, and sex may influence zinc concentration 
[207]. Therefore, it is debatable if serum or plasma zinc 
values represent zinc status adequately [200, 208]. Never-
theless, despite its inaccuracy, plasma zinc level is prob-
ably nowadays the best indicator measuring zinc status 
[209]. Another way to asses zinc status would be clini-
cally, whereas the clinical syndrome of acrodermatitis en-
teropathica with red, desquamating lesions on the hands 
and the nasolabial folds together with hair loss is pathog-
nomonic for zinc deficiency [208]. 
As zinc interferes with the intestinal absorption of 
iron, especially copper, oral supplementation should not 
be carried out for longer than 2–3 weeks [210, 211].
Conclusion
Western lifestyle, specifically western diet, is a major 
driving factor for the increased prevalence of IBD in in-
dustrialized and emerging countries. Increased intake of 
fats and/or proteins, reduced intake of fruits and vegeta-
bles, as well as the increase in the use of emulsifiers or 
other binding substances are among the most important 
candidate factors to promote inflammation in the intes-
tines of healthy subjects. However, as of today it remains 
unclear which of these individual nutritional factors are 
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primarily responsible for the recent epidemiological in-
crease in IBD.
Although there are countless books and websites on 
nutrition and IBD, there is little evidence to support re-
strictive dietary interventions in patients with IBD. 
Therefore, current recommendations to our patients 
should center around and encourage a healthy and bal-
anced diet based on unprocessed foods instead of restric-
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